BACKGROUND: Because fundoplication-related side effects are frequent, we evaluated laparoscopic mesh-augemented hiatoplasty (LMAH) as a potential treatment option for gastroesophageal reflux disease and/or symptomatic hiatal herania. LMAH aims to prevent reflux solely by mesh-reinforced narrowing of the hiatus and lengthening of the intra-abdominal esophagus. METHODS: Twenty-two consecutive patients with LMAH were evaluated prospectively using a modified Gastrointestinal Symptom Rating Scale questionnaire, pH measurement, manometry, and endoscopy. Follow-up was scheduled at 3 and 12 months after surgery. RESULTS: Total reflux decreased from 16.3% before surgery to 3.5% 3 months after surgery (P = .001). The reflux score decreased from 3.8 before surgery to 2.1 1 year after surgery (P = .001). The respective values of the indigestion score were 3.4 and 2.0 (P < .001). After surgery, all patients were able to belch. Vomiting was impossible only for 2 patients, and 90% of patients assessed their results as good to excellent. CONCLUSIONS: LMAH seems to be feasible, safe, and has no significant side effects.
BACKGROUND: Because fundoplication-related side effects are frequent, we evaluated laparoscopic mesh-augemented hiatoplasty (LMAH) as a potential treatment option for gastroesophageal reflux disease and/or symptomatic hiatal herania. LMAH aims to prevent reflux solely by mesh-reinforced narrowing of the hiatus and lengthening of the intra-abdominal esophagus. METHODS: Twenty-two consecutive patients with LMAH were evaluated prospectively using a modified Gastrointestinal Symptom Rating Scale questionnaire, pH measurement, manometry, and endoscopy. Follow-up was scheduled at 3 and 12 months after surgery. RESULTS: Total reflux decreased from 16.3% before surgery to 3.5% 3 months after surgery (P = .001). The reflux score decreased from 3.8 before surgery to 2.1 1 year after surgery (P = .001). The respective values of the indigestion score were 3.4 and 2.0 (P < .001). After surgery, all patients were able to belch. Vomiting was impossible only for 2 patients, and 90% of patients assessed their results as good to excellent. CONCLUSIONS: LMAH seems to be feasible, safe, and has no significant side effects.
Authors: Geoffrey Paul Kohn; Raymond Richard Price; Steven R DeMeester; Jörg Zehetner; Oliver J Muensterer; Ziad Awad; Sumeet K Mittal; William S Richardson; Dimitrios Stefanidis; Robert D Fanelli Journal: Surg Endosc Date: 2013-09-10 Impact factor: 4.584
Authors: Stavros A Antoniou; Oliver O Koch; George A Antoniou; Rudolph Pointner; Frank A Granderath Journal: Langenbecks Arch Surg Date: 2011-07-27 Impact factor: 3.445
Authors: Beat P Müller-Stich; Arianeb Mehrabi; Hannes G Kenngott; Hamidreza Fonouni; Michael A Reiter; Gani Kuttymoratov; Felix Nickel; Georg R Linke; Ivo Wolf; Jörg Köninger; Carsten N Gutt Journal: Surg Endosc Date: 2008-10-15 Impact factor: 4.584
Authors: Tobias Gehrig; A Mehrabi; L Fischer; H Kenngott; U Hinz; C N Gutt; Beat P Müller-Stich Journal: Langenbecks Arch Surg Date: 2012-07-31 Impact factor: 3.445
Authors: Georg R Linke; Andreas Zerz; Radu Tutuian; Francesco Marra; Rene Warschkow; Beat P Müller-Stich; Jan Borovicka Journal: J Gastrointest Surg Date: 2008-01-23 Impact factor: 3.452